Preliminary Financial Results Announcement - Accelerate Diagnostics, Inc. announced preliminary results for the quarter and year ending December 31, 2024 on January 10, 2025 [3] - The press release detailing the preliminary results is attached as Exhibit 99.1 and incorporated by reference [3] Regulatory and Filing Information - The information in Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act [4] - The report includes an Interactive Data File (XBRL) as Exhibit 104 [5] Executive Signatory - The report was signed by David Patience, Chief Financial Officer of Accelerate Diagnostics, Inc., on January 10, 2025 [8]

TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024."During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial ...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Today’s remarks will be followed by a ...

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.53%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of $0.55 per share when it actually produced a loss of $0.50, delivering a surprise of 9.0 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1072256 ( ...

Exhibit 99.1 Accelerate Diagnostics Reports Third Quarter 2024 Financial Results TUCSON, Ariz., November 7, 2024 -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVE system and the Gram-Negative assay. This quarter also marked a significant milestone with FDA clearance of our Accelera ...

TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024."We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay.  This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutio ...

TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results.To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 mi ...

Accelerate Diagnostics, Inc. (AXDX) has secured FDA 510(k) clearance for its Accelerate Arc system and BC kit, designed for use with Bruker's MALDI Biotyper CA system (MBT-CA System) and MBT-CA Sepsityper software extension.Accelerate Diagnostics' automated platform simplifies the preparation of positive blood culture samples for direct microbial identification using Bruker's MBT-CA system, removing the overnight culture requirement. The Arc system reduces wait times for critical diagnostic results, which i ...

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR)Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samplesTUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated ...